A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda

Table 3 Primary outcomes for isoniazid prevention therapy

Patient characteristics	Numbers (n)	Percentages (%)
Developed active TB disease over six months period^a
Yes	0	0
No	993	100
Primary outcome^b
Completed	901	89.2
Never completed/unknown outcome	109	10.8
Total	1010	100
Other outcomes^c
Lost to follow up	17	1.7
Stopped treatment	92	9.1
Unknown	16	1.6
Died	0	0
Reason for stopping^d
Side effects	41	44.6
Treatment interruption	51	55.4
Total	92	100

^aOnly patients with known outcome and includes those who completed and those who stopped treatment
^bExcludes patients with unknown outcome
^cExcludes patients who completed treatment and is expressed out of the total cohort of 1026
^dIncludes only patients who stopped treatment